ArticleOncogene2019

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Angie M Torres-Adorno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.